Exchange: NYSE·Updated 11:15 AM EDT

PFE News

News
all
press releases
Can Pfizer Overcome Its COVID and Patent Cliff Headwinds?
PFE faces COVID revenue declines and a patent cliff, but new products, acquisitions and a strong pipeline could fuel growth from 2029.
Zacks
More News
The Fauci Diary Entry That Explains Why MAHA Must Exist
The Fauci Diary Entry That Explains Why MAHA Must Exist Authored by Peter Navarro via The Epoch Times, I fought Anthony Fauci across a White House table over the China travel ban, lockdowns, masks, hydroxychloroquine, vaccines, and boosters. Yet one of the most damning pieces of...
Zero Hedge
How Concerned Should Income Investors Be About Pfizer's Dividend?
Key PointsPfizer is one of the world's best-known drug companies, offering a well-above-market dividend yield...
Nasdaq News: Markets
Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For?
Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For...
Yahoo! Finance: News
Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit?
PFE's non-COVID growth, oncology pipeline and cost cuts offer a path forward as COVID sales fall and patent losses loom.
Zacks
Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now
Key PointsPharmaceutical giant AbbVie has a longer history of dividend growth than Pfizer...
Nasdaq News: Markets
MRNA Stock Soars 143% in a Month: Time to Buy, Hold or Sell?
Moderna stock surges 143% in a month on positive cancer therapy results, but competition and valuation raise key questions for investors.
Zacks
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 10:45 a.m. EDT. To listen to the webcast...
Business Wire
Lilly Builds Neuroscience into a New Long-Term Growth Driver
Lilly is expanding its neuroscience pipeline through strong growth and M&A, aiming to build a new long-term driver beyond cardiometabolic therapies.
Zacks
This Is What I'd Do With Pfizer Stock Right Now
This Is What I'd Do With Pfizer Stock Right Now...
Yahoo! Finance: News

Advertisement|Remove ads.